Close
Novotech
Jabsco PureFlo 21 Single Use

Press Releases

Clasado announces positive results of clinical study of Bimuno(R) for Metabolic Syndrome

Clasado, the manufacturers and suppliers of Bimuno(R), a unique trans-galactooligosaccharide prebiotic, today announces the results of a clinical study on the use of the Bimuno (B-GOS) to alter bacteria in the human gastrointestinal tract as a candidate to...

e-Therapeutics to Raise GBP 40 Million to Advance Lead Cancer Drug and Exploit Network Pharmacology Platform

Drug discovery and development company e-Therapeutics plc proposes to raise GBP 40 million (approximately GBP 39million net) through an issue of new ordinary shares to existing and new institutional investors. The new shares will be...

Labeling Considerations in the European Union and its Impact on Global Labeling Compliance

Designing a product label is a long and complex process, from the amount of time that is needed, to creating a label that is compliant with the current FDA regulations. Pharmaceutical companies are constantly managing...

Alpha Szenszor Inc. and Technion Announce Joint Venture in Lung Cancer Diagnostics

Alpha Szenszor Inc., a leading provider of carbon nanotube based sensors and the Technion -Israel Institute of Technology have announced a joint venture for the commercialization of advanced lung cancer diagnostics based on Volatile Organic Compound (VOC) detection...

GE Healthcare Works to Speed Up Fight Against Cancer

GE Healthcare’s work to accelerate cancer innovation and improve care for cancer patients reached new milestones in advanced technology. The campaign is founded on GE Healthcare’s integrated portfolio, which is uniquely positioned to drive...

Rhenovia Pharma recognized as the world leader in biosimulation of the central nervous system

Rhenovia Pharma, a biotechnology company created in 2007, today announces it has had its position confirmed as world leader in the field of biosimulation for research into drugs for treating diseases of the central nervous system. ...

Cerulean Announces First Patient Dosed in Randomized Phase 2 Study of CRLX101 in Advanced Small Cell Lung Cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase 2 study of its lead candidate, CRLX101, in patients with extensive-stage small cell lung cancer...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »